ENTA ENANTA PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1177648 · Fiscal year ends 09/30
Financial factors as of 2026-09-30 (2026Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-3.6%
TTM net income YoY16.7%
TTM EPS YoY38.8%
Revenue 3-yr CAGR-7.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-99.0%
Net margin-108.3%
FCF margin-67.9%
EBITDA margin-91.4%
Returns
ROE-94.2%
ROA-24.5%
ROIC (approx.)-106.7%
Asset turnover0.23x
Leverage & solvency
Liabilities / assets70.9%
Debt / equity0.00x
Current ratio3.78x
Interest coverage-4.43x
Cash quality & payout
Operating cash flow / net income0.62x
Accruals ratio-9.2%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q4*2026-09-30 | 2026Q32026-06-30 | 2026Q22026-03-31 | 2026Q12025-12-31 | 2025Q4*2025-09-30 | 2025Q32025-06-30 | 2025Q22025-03-31 | 2024Q12024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $12.87M | $14.36M | $17.16M | $18.61M | $15.12M | $18.31M | $14.93M | $16.96M |
| R&D expense | $26.12M | $22.13M | $19.44M | $20.86M | $23.81M | $27.21M | $28.07M | $27.66M |
| SG&A expense | $8.79M | $9.47M | $9.57M | $9.01M | $9.70M | $10.00M | $11.39M | $12.85M |
| Operating income | -$22.04M | -$17.24M | -$11.85M | -$11.25M | -$18.39M | -$18.89M | -$24.53M | -$23.54M |
| Interest expense | $3.54M | $4.13M | $3.32M | $3.08M | $2.39M | $1.62M | $1.71M | $1.96M |
| Pretax income | -$23.75M | -$19.46M | -$13.08M | -$11.91M | -$18.67M | -$18.23M | -$23.95M | -$22.71M |
| Income tax | -$27,000 | $36,000 | $7,000 | $24,000 | $32,000 | $29,000 | -$1.30M | -$416,000 |
| Net income | -$23.72M | -$19.50M | -$13.09M | -$11.94M | -$18.70M | -$18.25M | -$22.64M | -$22.29M |
| EBITDA | -$20.88M | -$16.05M | -$10.64M | -$10.02M | -$17.10M | -$17.68M | -$23.32M | -$22.65M |
| EPS (basic) | — | -0.67 | -0.45 | -0.42 | — | -0.85 | -1.06 | -1.05 |
| EPS (diluted) | — | -0.67 | -0.45 | -0.42 | — | -0.85 | -1.06 | -1.05 |
| Weighted avg. shares (diluted) | — | 29.09M | 29.04M | 28.75M | — | 21.38M | 21.36M | 21.24M |
| Balance sheet | ||||||||
| Cash & equivalents | $20.27M | $33.42M | $34.93M | $37.44M | $32.30M | $44.81M | $60.21M | $84.35M |
| Short-term investments | $174.24M | $156.09M | $128.85M | $148.41M | $156.57M | $159.30M | $133.16M | $132.34M |
| Receivables | $5.86M | $6.53M | $7.81M | $8.49M | $6.88M | $8.33M | $6.79M | $7.72M |
| Current assets | $205.99M | $203.62M | $178.41M | $198.68M | $204.34M | $222.71M | $242.86M | $268.14M |
| PP&E, net | $30.86M | $31.94M | $33.11M | $34.31M | $35.40M | $36.62M | $37.57M | $37.37M |
| Total assets | $275.58M | $296.87M | $314.70M | $329.50M | $280.73M | $301.03M | $322.99M | $348.64M |
| Current liabilities | $54.46M | $54.17M | $46.44M | $44.73M | $48.55M | $44.55M | $45.95M | $49.05M |
| Total liabilities | $195.38M | $195.80M | $198.12M | $202.91M | $216.01M | $221.75M | $229.46M | $236.83M |
| Shareholders' equity | $80.19M | $101.07M | $116.59M | $126.59M | $64.72M | $79.28M | $93.54M | $111.82M |
| Shares outstanding | 29.14M | 29.12M | 29.06M | 29.02M | 21.39M | 21.38M | 21.38M | 21.33M |
| Cash flow statement | ||||||||
| Operating cash flow | -$13.73M | -$9.97M | -$7.16M | -$11.70M | -$6.49M | $17.51M | -$13.49M | -$16.80M |
| Capital expenditure | $41,000 | $7,000 | $15,000 | $143,000 | $1.46M | $155,000 | $2.54M | $8.74M |
| Free cash flow | -$13.77M | -$9.98M | -$7.17M | -$11.84M | -$7.95M | $17.35M | -$16.03M | -$25.55M |
| Investing cash flow | $4.17M | $14.01M | $11.94M | -$47.30M | $2.30M | -$26.48M | -$4.37M | $68.90M |
| Financing cash flow | -$3.58M | -$5.54M | -$7.29M | $64.14M | -$8.32M | -$6.42M | -$6.89M | -$4.99M |
| Depreciation & amortization | $1.16M | $1.19M | $1.21M | $1.23M | $1.28M | $1.21M | $1.20M | $889,000 |
| Stock-based compensation | $2.79M | $3.68M | $3.75M | $3.81M | $4.03M | $4.18M | $4.69M | $5.67M |
Free plan shows the latest 8 periods; Pro shows all 60 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.